Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2022-05-06 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房关于2021年年度报告的更正公告
Regulatory Filings Classification · 95% confidence The document is titled as a correction announcement regarding the 2021 Annual Report of the company. It details specific corrections to financial data previously disclosed in the 2021 Annual Report and the 2021 Annual Audit Report. The document explicitly states that the corrections do not affect the company's financial condition or operating results for 2021. It also mentions that the corrected 2021 Annual Report will be disclosed on the stock exchange website. The document length is about 5128 characters, which is relatively short and primarily serves to correct previously published annual report data rather than presenting the full annual report itself. Therefore, this document is an announcement about corrections to the Annual Report, not the Annual Report itself. According to the "Menu vs Meal" rule, such a correction announcement should be classified as a Regulatory Filing (RNS) rather than a 10-K (Annual Report).
2022-05-06 Chinese
控股股东、实际控制人关于股票交易异常波动征询函的回函
Regulatory Filings Classification · 95% confidence The document is a response letter to an inquiry about abnormal stock trading fluctuations. It contains statements from major shareholders and the actual controller of the company denying undisclosed material information or insider trading during the period of abnormal stock price movements. There are no financial statements, management discussion, or report data. The document is a regulatory communication related to stock trading and disclosure compliance, not a financial report or announcement of a meeting or vote. It fits best under Regulatory Filings (RNS) as a compliance-related disclosure letter.
2022-05-06 Chinese
益丰药房2021年年度报告（更正版）
Annual Report Classification · 100% confidence The document is titled "2021 年年度报告" which translates to "2021 Annual Report". It contains detailed financial data, management discussion and analysis, company overview, financial statements, and audit opinions. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes sections such as "管理层讨论与分析" (Management Discussion and Analysis), "公司治理" (Corporate Governance), "财务报告" (Financial Report), and detailed financial metrics for the year 2021. The presence of an audit report with an unqualified opinion is also noted, which is typical in annual reports. The document is not a brief announcement or a certification letter but a comprehensive yearly report covering company activity and full financial performance for the fiscal year 2021. Therefore, the correct classification is Annual Report (10-K). FY 2021
2022-05-06 Chinese
益丰药房股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a stock trading abnormal fluctuation announcement for the company 益丰大药房连锁股份有限公司. It details the stock price movements over specific dates, confirms no undisclosed material information, and warns investors about market risks. There is no financial data, no report attached or referenced as being published, and no mention of management changes, dividends, or other report types. This type of announcement is a regulatory disclosure about stock price abnormality, which fits best under Regulatory Filings (RNS) as it does not match any other specific category.
2022-05-06 Chinese
益丰药房投资者关系活动会议纪要（20220505）
Call Transcript Classification · 95% confidence The document is a transcript of an investor relations activity meeting held via conference call on April 29, 2022. It includes detailed discussions of the company's 2021 annual and 2022 first quarter operating results, financial performance, store expansion strategies, and responses to investor questions. The presence of a Q&A session and the format of the document as a meeting record strongly indicate it is a Call Transcript (CT). The document length is 2756 characters, which is consistent with a transcript rather than a full formal report. There is no indication that this is an official annual report, earnings release, or regulatory filing. Therefore, the best classification is Call Transcript (CT).
2022-05-05 Chinese
关于2022年第一季度主要经营数据的公告
Earnings Release Classification · 95% confidence The document is titled as an announcement regarding the company's main operating data for the first quarter of 2022. It contains key financial metrics such as revenue, net profit, cash flow, and segment breakdowns for the quarter, as well as operational data like store openings and closures. The document is relatively short (2911 characters) and focuses on quarterly performance data rather than a full comprehensive report. It does not appear to be a full interim or quarterly report with detailed financial statements, but rather a summary announcement of main operating data for the quarter. This fits best with the category of an Earnings Release (ER), which is an initial announcement of quarterly/periodical financial results with key highlights only. Q1 2022
2022-04-28 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.